Page last updated: 2024-09-04

atazanavir sulfate and Genetic Predisposition

atazanavir sulfate has been researched along with Genetic Predisposition in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alvarellos, M; Brummel, SS; Caudle, KE; Court, MH; Gammal, RS; Gaur, AH; Guillemette, C; Haas, DW; Haidar, CE; Iwuchukwu, OF; Klein, TE; Lennox, JL; Ratain, MJ; Schackman, BR; Whirl-Carrillo, M	1
Roca, B	1
Barreiro, P; Barrios, A; Corral, A; González-Lahoz, J; Jiménez-Nacher, I; Rendón, A; Rodríguez Nóvoa, S; Soriano, V	1

Reviews

2 review(s) available for atazanavir sulfate and Genetic Predisposition

Article	Year
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clinical pharmacology and therapeutics, 2016, Volume: 99, Issue:4 Topics: Atazanavir Sulfate; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Jaundice; Liver; Pharmacogenetics; Phenotype; Risk Assessment; Risk Factors	2016
Pharmacogenomics of antiretrovirals. Recent patents on anti-infective drug discovery, 2008, Volume: 3, Issue:2 Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir	2008

Article

Year

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Clinical pharmacology and therapeutics, 2016, Volume: 99, Issue:4

Topics: Atazanavir Sulfate; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Jaundice; Liver; Pharmacogenetics; Phenotype; Risk Assessment; Risk Factors

2016

Pharmacogenomics of antiretrovirals.

Recent patents on anti-infective drug discovery, 2008, Volume: 3, Issue:2

Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir

2008

Other Studies

1 other study(ies) available for atazanavir sulfate and Genetic Predisposition

Article	Year
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jan-15, Volume: 42, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Genes, MDR; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Odds Ratio; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; RNA, Viral; Viral Load	2006

Article

Year

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jan-15, Volume: 42, Issue:2

Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Genes, MDR; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Odds Ratio; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; RNA, Viral; Viral Load

2006